All News

Medication therapy management can change the trajectory of patient health outcomes. Here is how pharmacists can ensure adherence and compensation.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and COPD.

Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.

A roundtable session discussed the real-world implications of applying DIR fees at the point of sale rather than through retroactive clawback.

The company will be presenting the full BATURA study data as a late-breaker oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.

Although there has recently been an effort to improve pediatric pain treatment, it is still often underestimated and not adequately managed.

In case you missed it, this week we had stories about the availability of the first liquid nonstimulant for ADHD, pharmacy technicians as "vaccine champions," SGLT2i's heart-healthy benefits, and more.

Cologuard Plus is approved for adults aged 45 years and older who are at average risk for the disease.

Researchers aimed to determine whether or not opioids were appropriate for treating adolescents experiencing chronic pain.

Check out important updates from the FDA for the week of September 30.

Researchers suggest that vaccine champion programs could be a promising avenue to increasing immunization rates.

Many public health officials aren’t surprised by the decline in vaccine coverage, although its underlying causes present unique challenges.

Senators Ron Wyden and Sherrod Brown wrote a letter to the Federal Trade Commission calling to explore yet another PBM tactic impeding competition.

See what’s trending in pharmacy with a preview of the Drug Topics September/October issue.

This year’s meeting will take place from October 6 to 9 in Boston, Massachusetts.

Investigators compared semaglutide and other glucagon-like peptide-1 receptor agonists with dipeptidyl peptidase-4 inhibitors.

In posters presented at the Heart Failure Society of America 2024 Annual Meeting, researchers assessed how substance use disorders impact cardiovascular outcomes.

Among patients with heart failure, researchers aimed to understand the association between social detriments of health and physical frailty.

The once-daily, extended release, oral suspension medication was approved by the FDA in May 2024.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Lea Wolsoncroft of Remedies Pharmacy in Hoover, Alabama, discussed what is going on in her pharmacy practice.

Two posters presented at the Heart Failure Society of America 2024 Annual Meeting looked deeper into the topic of statin use in heart transplant recipients.

Researchers compared the cardiovascular outcomes of patients hospitalized for heart failure that did or did not experience diabetic emergencies.

Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.

Angiotensin neprilysin inhibitors have shown to reduce the risk of death and hospitalization due to heat failure, but high prescription costs are a current barrier.

Vaccination against respiratory viruses such as RSV and the flu are crucial to prevent adverse outcomes in patients with heart failure.

Left ventricular ejection fraction, brain natriuretic peptide, and heart failure-related hospitalizations were among the improved metrics.

Sara T. Thomason discuses the impact of stigma on pharmacists who are dealing with substance use disorder, the importance of mental health care, and how schools support pharmacy students dealing with addiction.